Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Head and Neck Cancer

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 26 articles:
HTML format
Text format



Single Articles


    September 2018
  1. FAKHRY C, Lacchetti C, Rooper LM, Jordan RC, et al
    Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline.
    J Clin Oncol. 2018 Sep 6:JCO1800684. doi: 10.1200/JCO.18.00684.
    PubMed     Text format     Abstract available


    August 2018
  2. JANJIGIAN YY, Bendell J, Calvo E, Kim JW, et al
    CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
    J Clin Oncol. 2018 Aug 15:JCO2017766212. doi: 10.1200/JCO.2017.76.6212.
    PubMed     Text format     Abstract available


    July 2018
  3. GEOFFROIS L, Martin L, De Raucourt D, Sun XS, et al
    Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial.
    J Clin Oncol. 2018 Jul 17:JCO2017762591. doi: 10.1200/JCO.2017.76.2591.
    PubMed     Text format     Abstract available


    June 2018
  4. TAO Y, Auperin A, Sire C, Martin L, et al
    Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial.
    J Clin Oncol. 2018 Jun 7:JCO2017762518. doi: 10.1200/JCO.2017.76.2518.
    PubMed     Text format     Abstract available


    March 2018
  5. MA BBY, Lim WT, Goh BC, Hui EP, et al
    Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).
    J Clin Oncol. 2018 Mar 27:JCO2017770388. doi: 10.1200/JCO.2017.77.0388.
    PubMed     Text format     Abstract available


  6. BHATIA AK, Burtness BA, Decker RH
    Postoperative Chemoradiation in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck.
    J Clin Oncol. 2018 Mar 16:JCO2018777987. doi: 10.1200/JCO.2018.77.7987.
    PubMed     Text format    


  7. PORCEDDU SV, Bressel M, Poulsen MG, Stoneley A, et al
    Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial.
    J Clin Oncol. 2018 Mar 14:JCO2017770941. doi: 10.1200/JCO.2017.77.0941.
    PubMed     Text format     Abstract available


    February 2018
  8. THAI AA, Rischin D
    High-Dose Cisplatin for Head and Neck Cancer Lives On.
    J Clin Oncol. 2018 Feb 2:JCO2017768614. doi: 10.1200/JCO.2017.76.8614.
    PubMed     Text format    


    December 2017
  9. QUON H, Vapiwala N, Forastiere A, Kennedy EB, et al
    Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline.
    J Clin Oncol. 2017;35:4078-4090.
    PubMed     Text format     Abstract available


  10. FAKHRY C, Zhang Q, Nguyen-Tan PF, Rosenthal DI, et al
    Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer.
    J Clin Oncol. 2017;35:4057-4065.
    PubMed     Text format     Abstract available


  11. NORONHA V, Joshi A, Patil VM, Agarwal J, et al
    Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.
    J Clin Oncol. 2017 Dec 8:JCO2017749457. doi: 10.1200/JCO.2017.74.9457.
    PubMed     Text format     Abstract available


    November 2017
  12. FORASTIERE AA, Ismaila N, Lewin JS, Nathan CA, et al
    Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
    J Clin Oncol. 2017 Nov 27:JCO2017757385. doi: 10.1200/JCO.2017.75.7385.
    PubMed     Text format     Abstract available


  13. HO AS, Kim S, Tighiouart M, Gudino C, et al
    Metastatic Lymph Node Burden and Survival in Oral Cavity Cancer.
    J Clin Oncol. 2017;35:3601-3609.
    PubMed     Text format     Abstract available


    October 2017
  14. VAN DEN WYNGAERT T, Helsen N, Carp L, Hakim S, et al
    Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography After Concurrent Chemoradiotherapy in Locally Advanced Head-and-Neck Squamous Cell Cancer: The ECLYPS Study.
    J Clin Oncol. 2017;35:3458-3464.
    PubMed     Text format     Abstract available


  15. CABANILLAS ME, de Souza JA, Geyer S, Wirth LJ, et al
    Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
    J Clin Oncol. 2017;35:3315-3321.
    PubMed     Text format     Abstract available


    August 2017
  16. HSU C, Lee SH, Ejadi S, Even C, et al
    Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
    J Clin Oncol. 2017 Aug 24:JCO2017733675. doi: 10.1200/JCO.2017.73.3675.
    PubMed     Text format     Abstract available


  17. BROSE MS, Worden FP, Newbold KL, Guo M, et al
    Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.
    J Clin Oncol. 2017;35:2692-2699.
    PubMed     Text format     Abstract available


  18. EBISCH RMF, Rutten DWE, IntHout J, Melchers WJG, et al
    Long-Lasting Increased Risk of Human Papillomavirus-Related Carcinomas and Premalignancies After Cervical Intraepithelial Neoplasia Grade 3: A Population-Based Cohort Study.
    J Clin Oncol. 2017;35:2542-2550.
    PubMed     Text format     Abstract available


    May 2017
  19. PETTY RD, Dahle-Smith A, Stevenson DAJ, Osborne A, et al
    Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.
    J Clin Oncol. 2017 May 24:JCO2016703934. doi: 10.1200/JCO.2016.70.3934.
    PubMed     Text format     Abstract available


  20. TRIFILETTI DM, Smith A, Mitra N, Grover S, et al
    Beyond Positive Margins and Extracapsular Extension: Evaluating the Utilization and Clinical Impact of Postoperative Chemoradiotherapy in Resected Locally Advanced Head and Neck Cancer.
    J Clin Oncol. 2017;35:1550-1560.
    PubMed     Text format     Abstract available


  21. SZTURZ P, Seiwert TY, Vermorken JB
    How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?
    J Clin Oncol. 2017 May 4:JCO2016718072. doi: 10.1200/JCO.2016.71.8072.
    PubMed     Text format    


    March 2017
  22. BAUML J, Seiwert TY, Pfister DG, Worden F, et al
    Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
    J Clin Oncol. 2017 Mar 22:JCO2016701524. doi: 10.1200/JCO.2016.70.1524.
    PubMed     Text format     Abstract available


    February 2017
  23. MARUR S, Li S, Cmelak AJ, Gillison ML, et al
    E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.
    J Clin Oncol. 2017;35:490-497.
    PubMed     Text format     Abstract available


  24. BARTLEY AN, Washington MK, Colasacco C, Ventura CB, et al
    HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.
    J Clin Oncol. 2017;35:446-464.
    PubMed     Text format     Abstract available


    January 2017
  25. FERRAROTTO R, Mitani Y, Diao L, Guijarro I, et al
    Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
    J Clin Oncol. 2017;35:352-360.
    PubMed     Text format     Abstract available


    December 2016
  26. JANSEN F, Krebber AM, Coupe VM, Cuijpers P, et al
    Cost-Utility of Stepped Care Targeting Psychological Distress in Patients With Head and Neck or Lung Cancer.
    J Clin Oncol. 2016 Dec 5:JCO2016688739.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: